Brolucizumab ELISA试剂盒(靶标：)

Brolucizumab ELISA Kit

货号：RB9T37014667

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37014667

中文名称
Brolucizumab ELISA试剂盒(靶标：)

英文名称
Brolucizumab ELISA Kit

应用
ELISA

登录号
P15692

检测方法
Colorimetric

检测范围
1.5625 ng/mL — 100 ng/mL

回收率
80-120%

样本类型
Plasma, Serum

检测类型
Quantitative

背景信息

Brolucizumab is the first and only single-chain variable fragment (scFv) targeting vascular endothelial growth factor (VEGF)-A. It has a smaller molecular weight (26 kDa). The mAb is undergoing evaluation as a treatment for neovascular age-related macular degeneration (nAMD). In June 2017, Novartis announced that the primary efficacy endpoint of non-inferiority to aflibercept (EYLEA®) in mean change in best-corrected visual acuity from baseline to week 48 was met in the Phase 3 HAWK (NCT02307682) and HARRIER (NCT02434328) studies, which included more than 1, 800 patients. The two studies compared the efficacy and safety of intravitreal injections of 6 mg brolucizumab or 3 mg brolucizumab (HAWK study only) versus 2 mg aflibercept in patients with nAMD. Of patients receiving 6 mg brolucizumab, 57% (HAWK) and 52% (HARRIER) were maintained exclusively on an every 12 week dosing interval immediately following the loading phase and continuing through week 48.54 Key secondary endpoints were also met. Novartis is developing a competitive, low cost of goods formulation, and expects to complete the PK study with antibody derived from the final manufacturing process to enable filing in 2018.

别名

ESBA-1008, ESBA1008, RTH258, 1531589-13-5

稳定性和储存

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

运输条件

2-8 ℃

For Research Use Only.